awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q26797535-3A30CBB5-8214-444D-9B60-CCFBB7F64E11
Q26797535-3A30CBB5-8214-444D-9B60-CCFBB7F64E11
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26797535-3A30CBB5-8214-444D-9B60-CCFBB7F64E11
Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma
P2860
Q26797535-3A30CBB5-8214-444D-9B60-CCFBB7F64E11
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26797535-3A30CBB5-8214-444D-9B60-CCFBB7F64E11
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
16f1aa8473769cae9ea0f731d8c5ee03220f357e
P2860
Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.